Analysis of Strategy for Extending Patent Protection of Rucaparib

作     者：Zhifeng Wang Zhifeng Wang

作者机构：Patent Examination Cooperation (Beijing) Center of the Patent Office CNIPA Beijing China 

出 版 物：《Journal of Biosciences and Medicines》 (生物科学与医学（英文）)

年 卷 期：2023年第11卷第9期

页      面：9-16页

学科分类：0202[经济学-应用经济学] 02[经济学] 020205[经济学-产业经济学] 

主　　题：Patent Portfolio Patent Analysis Rucaparib New Drug Research and Development Patent Protection 

摘      要：As a knowledge-intensive and promising strategic emerging industry, the biomedical industry has high entry thresholds, large R&D investment, long cycle, high risk and high return. In all technical fields, the biomedical industry has the highest dependence on intellectual property rights, and the protection of pharmaceutical intellectual property rights by domestic and foreign biomedical enterprises also runs through the whole process of drug research and development. Extending the patent protection period of drugs as well as forming and strengthening patent fortresses requires a patent network that surrounds drugs to maximize the value of intellectual property protection, which is also the focus of every pharmaceutical company with patent rights. By analyzing the patent portfolio of Clovis Oncology Company in the United States on Rucaparib and the patent portfolio of other companies or applicants on Rucaparib, we can have a clearer understanding of the strategy of extending the patent protection period of a new drug product.